Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

NEW YORK (AP) — The founder and former CEO of the failed cryptocurrency lending platform Celsius Network should face 20 years ...

With April 29 being Day 100 for U.S. President Donald Trump, his staff observed the day by touting the achievements of the administration’s first 100 days in office, especially new commitments made by ...

Recent health news highlights include Sandoz's criticism of EU drug pricing, a US-Mexico pact on pest control, advancements in cancer therapies, and significant corporate deals. Studies, policy ...

WESTFORD, Mass. (AP) — WESTFORD, Mass. (AP) — Kadant Inc. (KAI) on Tuesday reported first-quarter profit of $24.1 million. The Westford, Massachusetts-based company said it had net income of $2.04 per ...

American Assets Trust expects full-year funds from operations to be $1.87 to $2.01 per share. The company's shares have declined 29% since the beginning of the year. In the final minutes of trading on ...

JEFFERSON CITY, Mo. (AP) — The Missouri Supreme Court on Tuesday upheld a voter-approved ballot measure gradually raising the ...

Blue Heron Farm, in the town of Chilmark in Martha’s Vineyard, Massachusetts was used by the Obama family for three summers ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.